NASDAQ Careers: Find a Job Now
Web NASDAQ.com
Search
Save my stocks for next time

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

AMGN: Stock Quote & Summary Data

$ 55.38 0.68 1.21%
Nov. 20, 2009 Market Closed
Update Quotes: . Updates every 7 Seconds.
Amgen Inc.
AMGN | Amgen Inc. | Common Stock | Market : NASDAQ-GS

Last Sale
Change Net / %
Best Bid / Ask
1y Target Est: $ 70.00
Today's High / Low  / 
Share Volume
50 Day Avg. Daily Volume 7,552,674
Previous Close $ 56.06
52 Wk High / Low $ 64.76 / $ 44.96
Shares Outstanding 1,015,477,000
Market Value $ 56,237,116,260
P/E Ratio 11.26
Forward P/E (1yr) 10.91
Earnings Per Share $ 4.92
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield N/A
Beta 0.48
NASDAQ Official Open Price: $ 55.69
Date of NASDAQ Official Open Price: Nov. 20, 2009
NASDAQ Official Close Price: $ 55.38
Date of NASDAQ Official Close Price: Nov. 20, 2009

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

Have a Question About AMGN?

Ask your question about about Amgen Inc. (AMGN) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!

Hot Topics in NASDAQ Answers

The most popular questions & answers in the
NASDAQ Answers Community:


 Company Description (as filed with the SEC)

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) was incorporated in 1980 and is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. We operate in one business segment — human therapeutics. We market human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. Our principal products include Aranesp® (darbepoetin alfa), EPOGEN ® (Epoetin alfa), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim) and Enbrel ® (etanercept). Aranesp® and EPOGEN® stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (“ESAs”). Aranesp® is used for the treatment of anemia both in supportive cancer care and in nephrology. EPOGEN® is used to treat anemia associated with chronic renal failure (“CRF”).  ... More ...  

Get ETF News, Commentary, Tools & more...

Visit the new NASDAQ.com ETFs hub Now

 Company News for AMGN

ImmunoGen Reveals Second License Taken By Amgen For Right To Use Its TAP Technology - Quick Facts
- RTT News  11/19/2009 6:01PM
This Stock Is a Train Wreck
- The Motley Fool  11/19/2009 3:17PM
Follow the Smart Money
- The Motley Fool  11/19/2009 12:47PM
The Type of Stock You Should Never, Ever Buy
- The Motley Fool  11/18/2009 4:01PM
These Stocks Will Burn You
- The Motley Fool  11/18/2009 2:04PM
Amgen To Present At Lazard Capital Healthcare Conference; Webcast At 9:30 AM ET
- RTT News  11/18/2009 6:48AM
Amgen to Present at Lazard Capital Healthcare Conference
- PR Newswire  11/16/2009 6:06PM
 

Consensus Recommendation


Analyst Info

Annual EPS Est: $ 5.03
Quarterly EPS Est: $ 1.21
PEG Ratio: 1.46
Mean Recommendation:
View Summary/View All
1.92